Shenzhen Kangtai Biological Products Co., Ltd. (300601)
Market Closed
10 Aug, 06:57
XSHE XSHE Primary ¥
12. 75
-0.1
-0.7782%
¥
18.27B Market Cap
22.66 P/E Ratio
0.36% Div Yield
16.56M Volume
0.95 Eps
¥ 12.85
Previous Close Want to track 300601 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
300601 closed today lower at ¥12.75, a decrease of -0.7782% from yesterday's close, completing a monthly increase of 12.6325% or ¥1.43. Over the past 12 months, 300601 stock lost -13.7348%.
300601 pays dividends to its shareholders, with the most recent payment made on Jun 11, 2026. The next estimated payment will be in In 10 months on Jun 11, 2027 for a total of ¥0.035.
The last earnings report, released on Apr 22, 2026, missed the consensus estimates by -0.0392%. On average, the company has fell short of earnings expectations by -0.0486%, based on the last three reports.
Shenzhen Kangtai Biological Products Co., Ltd. has completed 2 stock splits, with the recent split occurring on Jun 02, 2022.
The company's stock is traded on one exchange.
300601 Chart
People also search for
Shenzhen Kangtai Biological Products Co., Ltd. (300601) FAQ
What is the stock price today?
The current price is ¥12.75.
On which exchange is it traded?
Shenzhen Kangtai Biological Products Co., Ltd. is listed on XSHE.
What is its stock symbol?
The ticker symbol is 300601.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.36%.
What is its market cap?
As of today, the market cap is 18.27B.
Has Shenzhen Kangtai Biological Products Co., Ltd. ever had a stock split?
Shenzhen Kangtai Biological Products Co., Ltd. had 2 splits and the recent split was on Jun 02, 2022.
Shenzhen Kangtai Biological Products Co., Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Xiang Miao CEO | XSHE Exchange | CNE100002Q33 ISIN |
| CN Country | 1,913 Employees | 11 Jun 2026 Last Dividend | 13 Jun 2018 Last Split | - IPO Date |
Overview
Shenzhen Kangtai Biological Products Co., Ltd., established in 1992 and headquartered in Shenzhen, China, specializes in the research, development, production, and sale of a wide array of human vaccines. The company plays a pivotal role in public health through its contributions to vaccinology, focusing on the innovation and availability of vaccines for various infectious diseases prevalent in China.
Products and Services
Shenzhen Kangtai Biological Products Co., Ltd. offers an extensive portfolio of vaccines, covering a range of diseases and conditions. Their product offerings include:
- Cell-Free Whitebait B-Type Haemophilus Influenzae Combined Vaccine: This vaccine targets Haemophilus influenzae type b, preventing diseases caused by this bacterium, such as meningitis and pneumonia.
- SARS-COV-2 Vaccine: Developed to prevent COVID-19, this vaccine is a crucial part of global efforts to combat the coronavirus pandemic.
- Recombinant Hepatitis B Vaccine: Aimed at preventing Hepatitis B, a serious liver infection, this vaccine is a key element in public health strategies to control the spread of viral hepatitis.
- 23-Valent Pneumococcal Polysaccharide Vaccine: This vaccine protects against pneumococcal disease caused by 23 of the most common or dangerous strains of the Streptococcus pneumoniae bacteria.
- Diphtheria Tetanus Acellular Pertussis and Haemophilus Influenzae Type B Combined Vaccine: A combination vaccine that offers protection against four diseases: diphtheria, tetanus, pertussis (whooping cough), and Haemophilus influenzae type b.
- Haemophilus Influenzae Type B Conjugate Vaccine: Specifically targets Haemophilus influenzae type b to protect against a variety of serious conditions it can cause.
- Measles and Rubella Combined Vaccine: This combined vaccine helps in the control and elimination of measles and rubella, two highly infectious diseases.
- 13-Valent Pneumococcal Conjugate Vaccine: Protects against diseases caused by 13 types of Streptococcus pneumoniae, including pneumonia, meningitis, and sepsis among others.
- Rabies Vaccine: Provides immunity against rabies, a deadly virus that affects the brain and central nervous system.
- Inactivated Poliomyelitis Vaccine: A key vaccine in the global effort to eradicate polio, offering protection against this paralyzing disease.
- Live Attenuated Varicella Vaccine: Designed to prevent chickenpox, a common and sometimes serious childhood illness.
- HIB Conjugate Vaccine: Another formulation targeting Haemophilus influenzae type b, emphasizing the company's focus on combating bacterial meningitis and associated infections.
Contact Information
Address: Kangtai Group Building, Shenzhen, China, 518057
Phone: 86 755 26988558
Website: https://www.biokangtai.com
